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Rotavirus (RV) infections cause severe diarrhea in infants and young children worldwide. Vaccines are available but cost prohibitive
for many countries and only reduce severe symptoms. Vaccinated infants continue to shed infectious particles, and studies show
decreased efficacy of the RV vaccines in tropical and subtropical countries where they are neededmost. Continuing surveillance for
new RV strains, assessment of vaccine efficacy, and development of cost effective antiviral drugs remain an important aspect of RV
studies.This study was to determine the efficacy of antioxidant and anti-inflammatory stilbenoids to inhibit RV replication. Peanut
(A. hypogaea) hairy root cultures were induced to produce stilbenoids, which were purified by high performance countercurrent
chromatography (HPCCC) and analyzed by HPLC. HT29.f8 cells were infected with RV in the presence stilbenoids. Cell viability
counts showed no cytotoxic effects onHT29.f8 cells. Viral infectivity titers were calculated and comparatively assessed to determine
the effects of stilbenoid treatments. Two stilbenoids, trans-arachidin-1 and trans-arachidin-3, show a significant decrease in RV
infectivity titers. Western blot analyses performed on the infected cell lysates complemented the infectivity titrations and indicated
a significant decrease in viral replication. These studies show the therapeutic potential of the stilbenoids against RV replication.
1. Introduction
The mechanisms of RV-induced diarrhea are multifacto-
rial and include both secretory and malabsorptive diar-
rhea components. Despite much effort, we do not have a
complete understanding of RV pathophysiology [1]. Vaccine
strategies against RV-associated diarrhea aim at stimulating
the immune system using either attenuated live RV or RV
proteins [2].There are two licensed RV vaccines in theUnited
States, RotaTeq, produced by Merck, and Rotarix, produced
by GlaxoSmithKline. Both are effective in preventing severe
diarrhea in vaccinated children [3, 4]. Recently, a newRVvac-
cine, Rotavac, was developed using a strain of the RV that was
isolated, manufactured, and tested in India by Hyderabad-
based Bharat Biotech International, Ltd. [5]. These vaccines
are designed to protect against common RV strains and
therefore are dependent on the genetic stability of the viruses.
Reassortment events are common and may lead to new
virulent RV strains that may not be averted by the current
vaccines [6]. Likewise, the zoonotic nature of RV infections
supports the argument to continue to survey for emerging RV
strains arising from interspecies transmission with potential
of vaccine failures [7]. The licensed RV vaccines mentioned
above are less efficacious in countries of sub-Saharan Africa
and SEAsia where they are neededmost [8–11]. Furthermore,
high costs, limited availability, and poor logistics for the
distribution of the vaccines are challenging problems for the
developing world [3]. Consequently, the development of cost
effective, easily distributed, novel, and host-oriented antiviral
paradigms is needed that affect a wide range of RV strains and
reduce the disease burden of RV infections. Taking advantage
of the antioxidant and anti-inflammatory properties of a
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natural product to treat RV infections meets the principles
of a novel therapeutic strategy that has an antiviral effect.
Stilbenoids are phenolic compounds derived from the
phenylpropanoid/acetate pathway. Among these compounds,
trans-resveratrol (t-Res) is the most extensively studied stil-
benoid which demonstrates strong antioxidant and chemo-
preventive properties [12]. Additionally, studies examining
resveratrol and its derivatives have demonstrated antiviral
properties. Resveratrol strongly inhibits the replication of
influenza virus in MDCK cells and improves survival and
decreased pulmonary viral infectivity titers in influenza
virus-infected mice. Furthermore, resveratrol exhibited no
toxic effects in vitro or in vivo [13]. However, another study
tested the effects of 20 𝜇M and 40 𝜇M concentrations of
resveratrol incubated for 24 and 48 hours postinfection with
polyomavirus in 3T3 and HL60 cells. The results showed
cytotoxicity in a time- and dose-dependent manner and
inhibition of polyomavirus DNA synthesis. There was no
cytotoxic effect to either cell line with 0.02% dimethyl sulfox-
ide (DMSO) alone [14]. Another study identified resveratrol
derivatives with potent anti-HSV-1 and HSV-2 activity. Sev-
eral trimeric and tetrameric derivatives showed antiherpetic
activity at single-digit micromolar concentrations [15].
Stilbenoids are produced by a group of plants which
includes grapes, peanuts, and some berries [12, 16, 17]. trans-
Piceatannol (t-PA) is a hydroxylated analog of resveratrol
found in grapes and in minor quantities in peanuts. trans-
Arachidin-1 (t-A1) is a prenylated (3-methyl-1-butenyl) ana-
log of piceatannol, whereas trans-arachidin-3 (t-A3) is a
prenylated (3-methyl-1-butenyl) analog of resveratrol (Fig-
ures 1(a)–1(d)). Both t-A1 and t-A3 are produced in peanuts
upon fungal challenge. These stilbenoids can be extracted
from some plants but are not suitable for many applications
in the food/pharmaceutical sectors due to the overall low
concentration of stilbenoids in the plant extracts. To deliver
a highly defined and stilbenoid-enriched product, hairy root
cultures of peanut (A. hypogaea) have been established in
a bioproduction system that produces increased levels of
stilbenoids, including t-A1 and t-A3, upon treatment with
elicitors [18, 19]. t-PA and t-Res are commercially available,
but t-A1 and t-A3 are still in an experimental stage resulting
in an opportunity to explore new antiviral biological activity.
This study assessed the therapeutic potential of four
stilbenoids, t-Res, t-PA, t-A1, and t-A3 (Figures 1(a)–1(d)),
to inhibit RV infections in culture using a cloned human
intestinal cell line, HT29.f8 [20].The hypothesis for this work
is that stilbenoidswillmodulate the viral load of RVgenerated
during an infection. Two sets of experiments were performed
in which different concentrations of the stilbenoids and two
time points postinfection were evaluated. To determine the
effect of the stilbenoids on the amount of virus produced
during an infection, viral infectivity titers were determined
using the supernatants for each of the different treatments
(10 𝜇M and 20𝜇M stilbenoids) collected at 12 and 24 hours
postinfection (hpi). The viral infectivity titers produced in
cells treated with the stilbenoids using a focus forming unit
(FFU) assay were compared to the virus infectivity titers
generated from RV infections alone and RV infections with
0.02% DMSO. The results were reported as infectious virus
particles/mL. Western blot analyses using the cell lysates
generated from these experiments demonstrated the presence
of the nonstructural RV protein (NSP4 nonstructural protein
4), a multifunctional viral protein that is essential for virus
replication and the production of infectious virus particles
[21].
2. Materials and Methods
2.1. Cells, Virus, and Reagents. The objective of the study was
to test the effect(s) of the four stilbenoids on RV replication in
HT29.F8 cells with variable concentrations of the stilbenoids
and different collection times. The dose was based on a pre-
vious study that assessed the effects of 20𝜇M resveratrol and
0.02% DMSO on two cell lines infected with polyomaviruses
[13, 14]. Another study utilized different concentrations of
DMSO and higher concentrations of resveratrol (50, 100, and
200𝜇M) on influenza A-infected cell line. Fifty and 100 𝜇M
concentrations of resveratrol were not cytotoxic to the cells
[13, 14]. Based on these results, we choose to test 10𝜇M
and 20𝜇M concentrations of each stilbenoid solubilized in
DMEM with 0.02% DMSO. A total of five experimental
sets were performed per stilbenoid. In the first experimental
set, cells were infected with SA114F RV at a multiplicity of
infection (MOI) of 2 as previously reported [22]. In the
second experimental set, 0.02% DMSO was added to the
RV infection to prove that 0.02% DMSO used to solubilize
the stilbenoids had no effect on cell viability or production
of RV. In the third and fourth experimental sets, 10 𝜇M or
20𝜇M concentrations of the stilbenoids, respectively, were
solubilized in 0.02% DMSO in DMEM, added to the RV
inoculum, and used to infect the cells. The fifth set was
uninfected HT29.f8 cells treated with the stilbenoids. The
sixth set was uninfected HT29.f8 cells treated with 0.02%
DMSO, and the seventh set was uninfected HT29.f8 cells
alone (Figure 2). Each experimental set was tested in four
wells of a 24-well tissue culture (TC) plate. The media
from the four wells were pooled and centrifuged and the
supernatants were stored at −80∘C and used to determine
viral infectivity titers. The cells were collected in PBS, frozen,
thawed 3 times, and centrifuged. The supernatants were
collected as the cell lysates and stored at −80∘C until used in
western blot assays. Viral infectivity titers were performed in
triplicate using two assays, the focus forming units (FFU) and
the plaque forming units (PFU) assays. Equal amounts of the
cell lysates were used inwestern blot assays to resolve the viral
proteins and probe for RV NSP4.
2.2. Bioproduction and Purification of the Stilbenoids. Hairy
roots of peanut cv. Hull (line 3) were cultured in at
least twenty 250mL flasks, each containing 50mL of MSV
medium as previously described [18, 23]. At day nine of
the hairy root culture, the spent medium from each flask
was removed and replaced with elicitation medium (fresh
MSV medium with 9 g/L methyl-𝛽-cyclodextrin (Cavasol
W7 M)) and incubated in the dark at 28∘C for an additional
72 h to induce synthesis and secretion of stilbenoids into
the culture medium as recently described [19]. After the
elicitation period, the culture medium was removed from
Advances in Virology 3
OH
OH
HO
Resveratrol
(a)
OH
OH
OH
HO
Piceatannol
(b)
OH
OH
HO
Arachidin-3
(c)
OH
OH
OH
HO
Arachidin-1
(d)
Figure 1: Chemical structures of the four stilbenoids tested. All compounds are shown in trans-isomers. (a) Resveratrol (t-Res). (b)
Piceatannol (t-Pa). (c) Arachidin-3 (t-A3). (d) Arachidin-1 (t-A1).
each flask and combined. This pooled medium was mixed
with an equal volume of ethyl acetate in a separatory
funnel to extract the stilbenoids as described before [18].
The ethyl acetate phase was recovered and was dried in a
Rotavapor (Buchi), and t-A1 and t-A3 were purified from the
extract by HPCCC as follows. The dried ethyl acetate extract
was resuspended in HPCCC solvent system (hexane : ethyl
acetate :methanol : water (4 : 5 : 3 : 3)) and injected into a
Spectrum (Dynamic Extractions) HPCCC system.The upper
phase of the solvent system was used as the stationary phase
and the chromatography was monitored at UV 340 nm.
Fractions were collected every 30 s, dried in a SpeedVac, and
analyzed by HPLC.
HPLC analyses were performed in a Dionex Summit
system, equipped with a photodiode array (PDA) detector.
The separation was performed on a SunFire C
18
, 5 𝜇m, 4.6 ×
250mmcolumn (Waters) at 40∘C at a flow rate of 1.0mL/min.
The mobile phase consisted of 2% formic acid in water (A)
andmethanol (B).Themethod started with 100%A for 1min.
Then a linear gradient was performed from 40% A and 60%
B to 35% A and 65% B (1 to 20min), followed by a linear
gradient from 35% A and 65% B to 100% B (20 to 25min).
Then the column was washed with 100% A for 5min (25 to
30min). Elicited peanut seed-derived t-A1 and t-A3were used
as reference standards [23].
Purity of the fractions obtained after HPCCC was moni-
tored byHPLCusingUV absorbance at 280, 320, and 340 nm.
Selected fractions also were checked for purity by mass
spectrometry using an UltiMate 3000 ultrahigh performance
liquid chromatography (UHPLC) system (Dionex, Thermo
Scientific) coupled with a LTQ XL linear ion trap mass
spectrometer (Thermo Scientific) as described in Marsh et
al. [24]. HPCCC fractions containing t-A1 and t-A3 with
over 95% purity based on HPLC analysis (UV 340 nm) were
combined, dried under a nitrogen stream, and used for viral
assays. The dry mass of the purified stilbenoids was recon-
stituted in 0.02% DMSO with 1𝜇g/m trypsin (Worthington
Biochemical, Lakewood,NJ) inDMEMmedium. To compare
the results between nonprenylated stilbenoids (t-Res and t-
PA) and their prenylated analogs (t-A3 and t-A1, resp.) the
synthetic/commercially available t-Res (Sigma-Aldrich) and
t-PA (Alexis) were used in this study.
2.3. Cell Lines and Virus. MA104 cells were obtained from
ATCC (Rockville, MD) and the HT29.F8 cells, a sponta-
neously polarizing cell line, were derived from the parent
human adenocarcinoma (HT29) intestinal line [20]. The cell
lines were confirmed to be free of mycoplasma contamina-
tion using the MycoFind mycoplasma PCR kit version 2.0
(Clongen Laboratories, LLC). RV SA11 clone 4F (P[1] and
G[3] genotype) [25] was grown and titered in MA104 cells
and stored at −80∘C. Stilbenoid efficacy against RVwas tested
using HT29.f8 cells.
2.4. Viability Assay. The percentage of live/dead cells was
calculated using the trypan blue dye exclusion assay as previ-
ously outlined [26]. Briefly, a cell suspension of ∼106 cells/mL
was diluted 1 : 1 with a 0.4% trypan blue solution and loaded
onto a hemocytometer. The number of stained cells and total
number of cells were counted, and the calculated percentage
of unstained cells was reported as the percentage of viable
cells. To determine if the 0.02% DMSO that was used to
solubilize the hydrophobic stilbenoids adversely affected the
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Figure 2:HT29.f8 Cell viability at 24 hpi with stilbenoids. (a) Resveratrol (t-Res). (b) Piceatannol (t-Pa). (c) Arachidin-1 (t-A1). (d) Arachidin-
3 (t-A3).
life span of HT29.F8 cells, viability assays were performed
with RV alone, RV with 0.02% DMSO, cells with 0.02%
DMSO, cells alone, and RV with 0.02% DMSO with 10 𝜇M
and 20𝜇M stilbenoids using the trypan blue cell exclusion
assay as described [26].
2.5. Virus Quantification. To test the biological activity of
the stilbenoids on RV infections, both FFU and PFU assays
were performed as previously described [27, 28]. MA104
cells were grown to 80% confluence in 24-well tissue culture
plates (Corning Life Sciences), starved for fetal bovine sera
12 h prior to infection, and then infected with RV SA114F.
Briefly, the SA114F RV stock was sonicated (5min using a cup
horn attachment and ice bath in a Misonix Sonicator 3000,
Misonix, Inc., Farmingdale, NY) and incubated in serum-free
DMEM with 1 𝜇g/mL trypsin (Worthington Biochemical,
Lakewood, NJ) for 30min at 37∘C.The activated viral inocu-
lum was incubated with the cells for 1 h at 37∘C in 5% CO
2
at an MOI of 2. The inoculum was replaced with serum-free
DMEM supplemented with 1 𝜇g/mL trypsin and incubated
for 12 and 24 hpi.The supernatants were collected, clarified at
300×g for 5min, and stored at −80∘C.The cells were washed
in cold Dulbecco’s PBS, 1X (Caisson Laboratories, Smithfield,
UT), and released from the plates using a 0.25% trypsin-
EDTA solution (1X) (Caisson Laboratories, Smithfield, UT).
After the addition of DMEM with 5% FBS, the cells were
resuspended in cold PBS and dilutions were prepared for
live/dead cell counts (see Section 2.4). The balance of the
cells was used to prepare cell lysates by subjecting them
to repeated freeze-thaws three times, clarified at 300×g
for 10min. Media (supernatant) were collected, clarified at
300×g for 10min, and stored at −80∘C. Both the cell lysates
and supernatants were stored at −80∘C. Viral infectivity
titers were done in triplicate by indirect immunofluorescent
staining of MA104 monolayers infected with serial dilutions
of the supernatants. The average number of fluorescent foci
was calculated for three wells and used to determine the
number of focus forming units/mL (FFU/mL) [29]. Since
the RV viral infectivity titers are critical to our conclusion,
two assays were used. The FFU data showed no difference
in viral infectivity titers at 12 hpi using 10𝜇M concentrations
(data not shown). Therefore, we chose to perform plaque
forming unit (PFU) assays comparing the two controls, RV
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Figure 3: HPLC analysis of stilbenoids.The 𝑥-axis is time inminutes, and the 𝑦-axis is the absorbance at 340 nm. (a) HPLC chromatogram of
ethyl acetate extract of the medium of hairy root culture of peanut treated with methyl-𝛽-cyclodextrin for 72 h. Compounds: (1) arachidin-1
and (2) arachidin-3. (b) HPLC chromatogram of (1) arachidin-1 purified by HPCCC. (c) HPLC chromatogram of (2) arachidin-3 purified by
HPCCC.
alone and RV with 0.02% DMSO to 20𝜇M of the stilbenoids
at 24 hpi. Plaque forming assays were performed in triplicate
as outlined above for the FFU assays, except after the 1-hour
infection; the virus inoculum was replaced with 3mL of a
medium overlay (1 : 1 mixture of 1.2% agarose (Apex Low
Melting Point Agarose, Genesee Scientific Inc.) and complete
2 × MEM containing 0.5 𝜇g/mL trypsin) and incubated at
37∘C in 5% CO
2
for 3 to 4 days or until plaques became
visible. A neutral red overlay (1 : 1 mixture of 1.2% agarose
with an equal volume of serum-free 2 × MEM containing
50𝜇g/mLneutral red)was prepared and 2mLperwell of stain
overlay was added on top of the first agarose/mediumoverlay.
The six-well plates were incubated at 37∘C until plaques were
visible (approximately 4 to 24 h).The individual plaques were
counted, and the titers were calculated as follows: number of
plaques × 1/dilution factor × 1/(mL of inoculum) = PFU/mL.
2.6. Statistical Analysis. Data are expressed asmean± SD, and
comparisons were statistically evaluated by analysis of vari-
ance (ANOVA) and Student’s 𝑡-tests using Excel (significance
level, 𝑝 ≤ 0.05).
2.7. Protein Quantification and Western Blot Assays. The
micro bicinchoninic acid (BCA) protein assay was employed
to quantify protein concentrations using bovine serum albu-
min as the standard per manufacturer’s protocol (Thermo
Scientific Pierce). One microgram of total protein from each
sample was separated by 12.5% SDS-PAGE, electroblotted
onto nitrocellulose membranes, and probed with NSP4
peptide-specific antibodies [30, 31] and reactive bands were
visualized by the addition of HRP-conjugated IgG and Super
Signal West Pico chemiluminescent substrate (Pierce) fol-
lowed by exposure to Kodak X-OMAT film [22, 32, 33].
3. Results and Discussion
3.1. Bioproduction of Stilbenoids in Hairy Root Cultures of
Peanut. Toproduce the stilbenoids t-A1 and t-A3we used our
previously established hairy root line 3 from peanut cv. Hull.
These hairy roots are capable of synthesizing and secreting t-
Res, t-A1, and t-A3 into the culture medium upon treatment
with the elicitor sodium acetate [18]. Depending on the
period of elicitor treatment, the levels and types of stilbenoids
found in themedium can bemodified [18]. To study the effect
of other elicitors on production of t-A1 and t-A3 we tested
different elicitors, including methyl-𝛽-cyclodextrin (CD). In
preliminary experiments different doses of CD were added
to the hairy root cultures for different periods between 0
and 96 h (data not shown). A 72 h treatment of 9 g/L CD
was selected based on production of the highest levels of t-
A1. As shown in Figures 3(a)–3(c), t-A1 and t-A3 were the
major stilbenoids present in the culture medium. t-Res was
present in very small amounts in these extracts. To purify
t-A1 and t-A3, ethyl acetate extracts were made from the
culturemedium and subjected toHPCCC (high performance
countercurrent chromatography). The solvent system was
adapted from a previously used CPC (centrifugal partition
chromatography) system which was effective in purifying t-
A1 and t-A3 from hairy root culture medium extracts [16].
The only modifications were the replacement of heptane
for hexane and ethanol for methanol. The separation was
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Figure 4: Quantification of progeny RV via focus forming units/mL (FFU/mL) at 24 hours postinfection. HT29.8 cells were infected with
RV, with RV containing 0.02% DMSO, or 10𝜇M/20𝜇M of (a) resveratrol (t-Res). (b) Piceatannol (t-Pa). (c) Arachidin-1 (t-A1) ∗𝑝 = 0.02 and
∗∗𝑝 = 0.001 and (d) arachidin-3 (t-A3) ∗𝑝 = 0.04, ∗∗𝑝 = 0.04, and ∗∗∗𝑝 = 0.02.
effective and comparable to the one achieved before [16].Thus
high yields of highly purified fractions of t-A1 and t-A3 were
achieved and were used in the antiviral assays.
3.2. Viability of HT29.F8 Cells in the Presence of 0.02%DMSO.
The percentage of live/dead cells was calculated using the
trypan blue exclusion dye assay (Figures 2(a)–2(d)). At 24 hpi,
the cell viability between all groups tested (HT29.f8 cells with
RV, HT29.f8 cells with RV and 0.02% DMSO, HT29.f8 cells
with RV and 10 𝜇M stilbenoids, HT29.f8 cells with RV and
20𝜇M stilbenoids, HT29.f8 cells with 20 𝜇M stilbenoids only,
HT29.f8 cells with 0.02% DMSO, and HT29.f8 cells only)
was not statistically significantly different (𝑝 < 0.05). These
data revealed that the addition of RV increases cell death,
but not significantly in the time frame examined. Also, the
addition of 20𝜇Mconcentrations of the stilbenoids decreased
cell viability but not significantly, while the addition of 0.02%
DMSO to the culture system did not adversely affect the
viability of the HT29.f8 cells in culture or diminish viral
replication (Figures 2(a)–2(d) and 6).These data demonstrate
that HT29.f8 cells were not adversely affected by RV, 0.02%
DMSO, or concentrations up to 20𝜇Mof the four stilbenoids
tested (t-Res, t-PA, t-A1, or t-A3).
3.3. The Effects of Stilbenoids on the Production of Infectious
Rotavirus Particles. Viral infectivity titers were determined
using FFU assays from the supernatants of RV-infected
HT29.f8 cells treated with stilbenoids (10 𝜇M and 20 𝜇M t-
Res, t-PA, t-A1, or t-A3). Supernatants collected at 12 hpi
were equivalent to the RV-infected control cells (data not
shown). Similarly, at 24 hpi, the 20𝜇M concentrations of
the nonprenylated stilbenoids, t-Res and t-PA both, demon
strated no change in the virus titer when compared to the
RV-infected control (Figures 4(a) and 4(b)). However at
24 hpi, the 10 𝜇M concentrations of t-A1 generated a tenfold
decrease in virus infectivity titer when compared to the RV-
infected control supernatants (𝑝 = 0.02), and the 20𝜇M
concentrations of t-A1 generated a twenty-fivefold decrease
in virus infectivity titer when compared to the RV-infected
control supernatants (𝑝 = 0.001) (Figure 4(c)), However,
there was a statistical difference between RV and RV with
DMSO with an eightfold decrease in virus infectivity titers
with RV and DMSO (𝑝 = 0.04) (Figure 4(d)). The 10 𝜇M
concentrations of t-A3 generated a ninefold decrease in virus
titer when compared to the RV-infected control supernatants
(𝑝 = 0.04), and the 20 𝜇M concentrations of t-A3 generated a
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Figure 5: Quantification of progeny RV in plaque forming units/mL (PFU/mL) at 24 hpi. HT29.8 cells were infected with RV, with RV
containing 0.02% DMSO, or 20 𝜇Mof (a) resveratrol (t-Res). (b) Piceatannol (t-Pa). (c) Arachidin-1 (t-A1). ∗Statistically significant 𝑝 = 0.02.
∗∗Statistically significant 𝑝 = 0.04. (d) Arachidin-3 (t-A3). ∗Statistically significant 𝑝 = 0.02. ∗∗Statistically significant 𝑝 = 0.02.
ninety-eightfold decrease in virus titer when compared to the
RV-infected control supernatants (𝑝 = 0.02) (Figure 4(d)).
Since the data generated with the FFU assays were critical
to test our hypothesis, plaque forming unit assays (PFU
assays) were performed to corroborate the results obtained
from the FFU assays. The PFU assays were performed using
the same supernatants that were utilized for the FFU assays.
Plaques were counted and the average of three experiments
was calculated and graphed as PFU/mL (Figures 5(a)–5(d)).
The data produced using the PFU assays showed similar
fold differences as shown with the FFU assays (Figures 5(a)–
5(d) and 4(a)–4(d), resp.). Using the ANOVA and Student’s
𝑡-test, the average and standard deviations were calculated
and graphed (Figures 4(a)–4(d) and 5(a)–5(d)). The PFU
experiments using t-Pa and t-Res showed no statistical differ-
ences between the controls, RV only and RVwith DMSO, RV
with 10 𝜇M t-Pa/t-Res, or RV with 20 𝜇M t-Pa/t-Res (Figures
5(a) and 5(b)). However, the experimental data from t-A1
PFU assays demonstrated a fifty-sevenfold difference from
the control, RV only, and a forty-ninefold difference from
the control, RV with DMSO that was statistically significant
(𝑝 = 0.02 and 0.04, resp.) (Figure 5(c)). Likewise, the exper-
imental data from 20𝜇M t-A3 PFU assays demonstrated
a fifty-fivefold difference from the control, RV only, and a
sixty-onefold difference from the control, RV with DMSO
that was statistically significant (𝑝 = 0.02 and 0.02, resp.)
(Figure 5(d)). Both assays show a significant decrease in RV
infectivity titers in the presence of 20 𝜇M t-A3.
3.4. Western Blot (WB) Analyses Imply Differences in RV
Replication. To complement and visualize the differences
demonstrated in the viral infectivity titers between RV alone
and RV with DMSO, 20𝜇M t-A1, and 20𝜇M t-A3, western
blot assays were performed as previously described [22, 32,
33]. Using equal amounts of protein of the corresponding
cell lysates, the nonstructural viral protein 4, NSP4, was
detected in all RV-infected cell lysates. The western blot data
of the RV and RV with DMSO both demonstrated relatively
equal amounts of multimeric forms and diglycosylated (fully
glycosylated), monoglycosylated, and cleavage fragments of
NSP4 and suggests that 0.02% DMSO does not affect the
amount of NSP4 produced during a RV infection (Figure 6,
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Figure 6: Western blot analysis of HT29.f8 cell lysates. Five
micrograms of HT29.f8 cell lysates was separated on a 12.5%
SDS-PAGE, electroblotted onto nitrocellulose membranes, probed
with rabbit anti-NSP4
150–175 peptide-specific and goat anti-rabbit
HRP-conjugated IgG, and visualized with Super Signal West Pico
chemiluminescent substrate (Pierce) followed by exposure to Kodak
X-OMAT film. (Lane 1) RV-infected HT29.f8 cells and (Lane 2)
RV-infected HT29.f8 cells with 0.02% DMSO, respectively, show
cleavage fragments and unglycosylated, mono-, diglycosylated, and
multimeric forms of NSP4. (Lane 3) RV-infected HT29.f8 cells with
20 𝜇M t-A1 and (Lane 4) RV-infected HT29.f8 cells with 20𝜇M t-A3
only show the diglycosylated form of NSP4. (Lane 5) HT29.f8 with
no virus showed NSP4 banding pattern.
Lanes 1 and 2). The presence of multimeric forms of NSP4
has been previously studied [34–36]. The results for RV with
t-A1 and t-A3 display a relatively small amount of the fully
glycosylated form of NSP4 (Figure 6, Lanes 3 and 4). This
indicates viral replication is negatively affected by 20𝜇M of
both t-A1 and t-A3. Cell lysates without RV (Figure 6, Lane
5) reveal no bands and show the specificity of the anti-NSP4
antibodies.
4. Conclusions
Our data show a dose- and time-dependent decrease in viral
progeny when RV and prenylated stilbenoids (t-A1 or t-A3)
were incubated with the human intestinal cell line HT29.F8.
The presence of the nonstructural viral protein NSP4 in the
western blot assays confirms the RV infection and indicates
the virus was replicating in the HT29.f8 cells. The prenylated
stilbenoids, t-A1 and t-A3, significantly are more lipophilic
than either of the nonprenylated t-Res or t-PA molecules.
The prenylated side chain increases the lipophilicity of the
molecules to which it is attached. Consequently, prenylation
promotes association with and penetration through cell
membranes. An increase in lipophilicity often correlates
positively with increased biological activity within different
groups of compounds of similar structure [37, 38]. Several
delivery systems including emulsions and nanoparticles have
been tested for the delivery of lipophilic, bioactive natural
products [39]. Depending on the application, these delivery
systems may be applicable to t-A1 and t-A3 and should be
tested to advance their development as potential therapeutic
agents.
Although the molecular mechanisms for the protective
effect of t-A1 and t-A3 are not known, the inhibition of
viral replication could be attributed to the antioxidative and
anti-inflammatory properties of the constituent stilbenoids.
In a previously published paper, t-A1 and t-A3 have been
shown to modulate the cannabinoid receptors at micromolar
levels [40]. The experimental data of this previous study
show that t-A3 acts as a competitive cannabinoid receptor 1
(CB1R) antagonist, whereas t-A1 antagonizes CB1R agonists
by both competitive and noncompetitive mechanisms [40].
It is interesting that the HT29 cell line, the parent cell
line of HT29.f8, expresses cannabinoid receptors [41], and
receptor expression should be investigated on the HT29.f8
cloned cells.These receptors are part of the endocannabinoid
signaling system which is well known to regulate gastroin-
testinal functions, such as gastric emptying, secretion, and
intestinalmotility [42, 43]. Hence it is reasonable to propose a
connection between the cannabinoid receptor functions and
the mechanism of RV gastroenteritis. In a study on colorectal
cancer, cannabinoid receptor (CB1 and CB2) agonists were
shown to have an effect on apoptosis through a TNF𝛼-
mediated increase in ceramide production [44]. Another
study on breast cancer shows the receptor agonists inhibit
adenylyl cyclase activity, cAMP, and PKA activity resulting in
the downregulation of gene transcription [45, 46]. A cAMP-
dependent PKA mechanism also appears to be important in
RV pathogenesis in a human intestinal cell line, Caco2 [47].
Recently, cannabinoid receptor antagonists were pro-
posed as potential therapeutic agents against hepatitis C virus
by modulating lipid homeostasis [48]. A study by Gaunt
et al. [49] using RV-infected MA104 cells demonstrates a
dose-dependent reduction in virus infectivity and viral RNA
production with the addition of TOFA (5-(tetradecyloxy)-2-
furoic acid), an inhibitor of the fatty acid synthase enzyme
complex [49]. Further, the infectivity of RV in ACC1 knock-
down cells was reduced by 8.5-fold (significant, 𝑝 = 0.01)
with siRNA directed against ACC1, the gene that encodes
the enzyme catalyzing the rate-limiting step of the palmitoyl-
CoA synthetic pathway. This strongly suggests that RV
infectivity is mediated through fatty acid metabolism [49] or
selected fatty acids.
Altogether, these data imply a possible antiviral mecha-
nism for t-A1 and t-A3 through modulation of the cannabi-
noid receptors and subsequent alteration of fatty acid
metabolism in the host cell. More studies are required to
confirm and expand our knowledge of the RV reducing prop-
erties of t-A1 and t-A3. Thus, these compounds potentially
could be used to design and develop more efficacious RV
therapeutic agents.
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